Abstract
NEWER GENERATION ANTIDEPRESsants should carry a broader warning of an increased risk of suicidal thoughts and behaviors in not only children and adolescents, but also young adults, recommended a US Food andDrugAdministration(FDA)advisory committee after considering new data fromtheagency.Butinanunprecedented step,thepanelalsorecommendedthatthe warningsincludeinformationonthebenefitsof treatingdepressionandtheriskof suicideassociatedwithuntreateddepression, based on emerging data that warnings about potential adverse effects of medicationsmayleadtoundertreatment and subsequent suicides. ThecommitteemetDecember13and voted 6 to 2 in favor of extending the existingblackboxwarnings,althoughmembers alsoagreed that thewarningshould address thebenefitsof treatmentand the risksassociatedwithdecliningtreatment, said Daniel S. Pine, MD, acting chair of thecommitteeandchiefofchildandadolescent researchat theNational Institute ofMentalHealth.TheFDAhasyet todecidewhether toaccept therecommendations, but typically the agency does follow its committees’ advice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
